Drug profile · INN
anidulafungin
ECALTA
anidulafungin (ECALTA) is a 1,3-beta-glucan synthase inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — anidulafungin
- US status
- approved
- Class
- Antiinfectives for systemic use (J02)
- Route
- INJECTION
- Patents
- 0
- Programs
- 3
- Data quality
- 0.84
Quick answer
anidulafungin (ECALTA) is a 1,3-beta-glucan synthase inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
1,3-beta-glucan synthase inhibitor
Primary target: 1,3-beta-glucan synthase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is anidulafungin?
anidulafungin (ECALTA) is a 1,3-beta-glucan synthase inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for anidulafungin?
ECALTA is a marketed brand name for anidulafungin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of anidulafungin?
anidulafungin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.